Hugo robot-assisted surgery system shows promise for urologic procedures
These results are expected to support submission of the Hugo system to the FDA for use in urologic procedures.
TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC
Data showed an overall CR rate of 82.4%.
Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation
The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.
Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025
Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.
CISTO: Radical cystectomy has key role in recurrent high-grade NMIBC
Twelve-month physical functioning scores were comparable between the radical cystectomy arm and the bladder-sparing therapy arm.
Safety, efficacy of vibegron sustained in men with OAB treated for BPH
The investigators reported an overall incidence of AEs of 29.6%.
FDA updates in urology: April 2025
A recap of the FDA submissions and regulatory decisions in urology from April 2025.
Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025
Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.
Pearls & Perspectives: Innovation in male fertility care with Larry Lipshultz, MD, at AUA 2025
Discover groundbreaking insights in urology as Larry Lipshultz, MD, shares innovative research and strategies for male fertility challenges.
Ultra-low PSA responses are more prevalent with darolutamide plus ADT
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
Cxbladder Triage may help patients avoid unnecessary cystoscopies
The study population was able to avoid 952 cystoscopies and 70 CT scans, according to the investigators.
Investigational ProVee System impresses in phase 3 trial in BPH
No device- or procedure-related serious AEs were observed through 12 months across the entire study population
Pearls & Perspectives: Martin Kathrins, MD, on MED3000 and learning from failed trials
Kathrins discusses the intricacies of leading a clinical trial and why "negative" trials are important to informing care strategies.
ARANOTE substudy highlights benefits of darolutamide in Black men
The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
CVAC 2.0 demonstrates efficacy for clearing stones less than 2 cm
The investigators reported a median stone clearance of 96.44%.
AUA 2025: GLP-1 RAs could improve sperm count in overweight men
New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.
Nogapendekin alfa inbakicept shows high CR, avoidance of cystectomy in NMIBC
In cohort A, the cystectomy-free rate at 36 months was 84%.
Pearls & Perspectives: Urology's role in GLP-1 RA treatments, with Hossein Sadeghi-Nejad, MD, and Nathalie Eid, BA
This episodes explores the evolving role of GLP-1 medications in testosterone management and their impact on male sexual health and fertility.
Most men in EMBARK trial recover T levels following treatment suspension
More than 80% of patients in both groups had a full recovery of testosterone.
Pearls & Perspectives: Updates in testosterone therapy, with Andrew Sun, MD at AUA 2025
Andrew Sun, MD, joins Pearls & Perspectives to discuss innovative approaches to testosterone therapy for enhanced health outcomes.
UGN-102 positions itself as an alternative to TURBT for low-grade NMIBC
"I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Sildenafil/Clomipramine Combo Boosts Outcomes in Premature Ejaculation
A phase 3 trial reveals a combination therapy for premature ejaculation significantly enhances treatment outcomes.
Estimated DOR of 2 years is seen with UGN-102 in LG-IR-NMIBC
The investigators reported that the median Kaplan-Meier estimate of DOR was 24.2 months.
Cretostimogene yields high CR rate in BCG-unresponsive NMIBC
"97% [of patients] remain progression free, and 84.5% avoided cystectomy, highlighting cretostimogene’s bladder-sparing potential,” said Mark D. Tyson II, MD, MPH.
Drinking water contaminants could increase risk of kidney stones, study finds
New research links higher drinking water contaminants to increased kidney stone risk.
CREST: Significant EFS boost seen with sasanlimab plus BCG in NMIBC
“In the patients with CIS, the probability of a continued complete response at 36 months was 92% vs 67.7%," said Neal D. Shore, MD, FACS.
Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC
Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC
Long-term data support radium-223 safety in mCRPC
Survey: New NMIBC treatments face slow uptake
